

Day-2 November 14, 2017

Track-A

Symposium Title: The long road to an HIV vaccine

08:00-10:30 **Co-chairs :** Richard Wyatt & Susan Zolla-Pazner

Keynote Speakers

08:00-08:30

Title: *Targeting selected epitopes in the development of an effective prophylactic HIV vaccine*
Susan Zolla-Pazner, Icahn School of Medicine at Mount Sinai

08:30-09:00

Title:
Hanneke Schuitemaker, Janssen Vaccines, The Netherlands

09:00-09:30

Title:
Louis Picker, Oregon Health & Science University, USA

09:30-10:00

Title: *Obstacles to and prospects for an effective HIV-1 vaccine*
Neil S. Greenspan, Case Western Reserve University, USA

10:00-10:30

Title: *Developing a preventive HIV vaccine requires solving inverse problems which is not feasible by rational vaccine design*
Marc Van Regenmortel, Strasbourg University, France

Coffee Break & Networking 10:30-11:00

11:00-13:05 **Session-I Co-chairs :** Marjorie Robert-Guroff & Neil S. Greenspan

11:00-11:25

Title: *HIV Env trimer immunogen design and modification to elicit neutralizing antibodies*
Richard Wyatt, Scripps Institute in La Jolla, CA USA

11:25-11:50

Title: *HIV/AIDS vaccine development: Defending the frontline*
Ruth Ruprecht, Texas Biomedical Research Institute, USA

11:50-12:15

Title: *Fundamental challenges to the development of an HIV vaccine*
Adan Rios, University of Texas Medical School in Houston, USA

12:15-12:40

Title: *Host genetic variability and HIV vaccines: a focus on low affinity Fcγ receptors*
Caroline T Tiemessen, National Institute for Communicable Diseases South Africa

12:40-13:05

Title: *Orally delivered mucosal vaccine targeting colorectal immunity protected SHIV transmission in macaques*
Yongjun Sui, National Cancer Institute, USA

Lunch & Networking 13:05-14:05

14:05-15:45

Session-II Co-chairs : Ruth Ruprecht & Jose Esparza

14:05-14:30

Title:
Angus Dalgleish, St George's, University of London

14:30-14:55

Title: *HIV vaccines: How we got where we are today and where we want to be in 2030?*
Jose Esparza, University of Maryland School of Medicine, USA

14:55-15:20

Title: *A sex bias in SIV vaccine protective efficacy: implications for HIV vaccine development*

Marjorie Robert-Guroff, National Cancer Institute, USA

15:20-15:45 **Title:** *A HIV vaccine based on MTVV prime Adv boost controlled viral reservoir and conferred long-term protection from SIVmac239 infection*
Ling Chen, Guangzhou Medical University, China

Coffee Break & Networking 15:45-16:10

Session-III Co-chairs : Hanneke Schuitemaker & Marc Van Regenmortel

16:10-16:35 **Title:** *The road to a pediatric HIV vaccine*
Kristina De Paris, UNC at Chapel Hill, USA

16:35-17:00 **Title:** *HIV Env antibody can provide sterilizing immunity in the strictest sense*
Klaus Überla, University Hospital Erlangen, Virology Institute, Germany

17:00-17:25 **Title:** *Mucosal vaccination with accessory antigens provides surprisingly robust protection against early SIV replication. Underappreciated role of location and immunodominance in vaccination against chronic infection?*
Peter Johannes Holst, University of Copenhagen, Denmark

17:25-17:50 **Title:** *Stabilization of gp120 outer domain for HIV vaccine immunogen design*
Shi-hua Xiang, University of Nebraska-Lincoln, Nebraska Center for Virology, USA

17:50-18:15 **Title:** *Identification of HIV-1 gp41 Residues that Modulate Envelope CD4 Reactivity*
Paul W. Keller, US Food and Drug Administration, USA

Day-3 Nov 15, 2017

Track-A (continues)

Session-IV Co-chairs: Catarina E. Hioe & Caroline T Tiemessen

08:00-08:25 **Title:** *Improving antibody response to targeted epitopes of HIV envelope by immune complex vaccines*
Catarina E. Hioe, Mount Sinai School of Medicine, USA

08:25-08:50 **Title:** *Control of heterologous SIVmac251 in macaques immunized with an HIV lentivector prototype*
Yahia Chebloune, University Grenoble Alpes, France

08:50-09:15
Title: *Critical review of Therapeutic Vaccines for the functional cure of the HIV Infection: lessons learned within clinical development programs, 2011-2017*
Shahin Gharakhanian, Shahin Gharakhanian MD Consulting LLC, USA

09:15-09:40 **Title:** *Efficacy of novel epithelial stem cell-based AIDS vaccine to induce mucosal immune responses and protect against SIV challenge in macaques*
Marie-Claire Gauduin, Texas Biomedical Research Institute, USA

09:40-10:05 **Title:** *Immunogen design to target HIV-1 envelope glycoprotein gp41*
Bing Chen, Boston Children's Hospital, USA

Coffee Break 10:05-10:30

10:30-10:55 **Title:** *New Technologies to evaluate vaccine-induced immune responses*
Spyros A. Kalams, Vanderbilt University Medical Center, USA

10:55-11:20 **Title:** *Safety and Immune Responses of Additional Boosting of the previous ALVAC®-HIV/AIDS VAX® B/E vaccines priming and boosting regimen (RV144)*
Punnee Pitisuttithum, Mahidol University, Thailand